Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma
By: Gang Peng, Rubo Cao, Jun Xue, Pindong Li, Zhenwei Zou, Jing Huang and Qian Ding
Open Access
|Jan 2014References
- 1. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;1765-77.
- 2. Greene FL, Page DL, Fleming ID, Fritz A. AJCC cancer staging manual. 6th edition. New York, NY: Springer; 2002.
- 3. Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol 2012;233-44.
- 4. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/ International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;6730-8.
- 5. Langendijk JA, Leemans CR, Buter J, Berkof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004;4604-12.
- 6. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004;2643-53.
- 7. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;631-7.
- 8. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005;1118-24.
- 9. Čarman J, Strojan P. Nasopharyngeal carcinoma in Slovenia, 1990-2003 (results of treatment with conventional two-dimensional radiotherapy). Rep Pract Oncol Radiother 2012;71-8.
- 10. Harrington K, Jankowska P, Hingorani M. Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol 2007;561-71.
- 11. Pajonk F, Vlashia E, McBridea WH. Radiation resistance of cancer stem cells: The 4 R’s of radiobiology revisited. Stem Cells 2010;639-48.
- 12. López-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA, Colás B. SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem 2011;89-98.
- 13. Rodriguez-Ubreva FJ, Cariaga-Martinez AE, Cortes MA, Romero-De Pablos M, Ropero S, López-Ruiz P, et al. Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. Oncogene 2010;345-55.
- 14. Tassidis H, Culig Z, Wingren AG, Härkönen P. Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells. Prostate 2010;1491-500.
- 15. Rodríguez-Ubreva FJ, Cariaga-Martinez AE, Cortés MA, Romero-De Pablos M, Ropero S, López-Ruiz P, et al. Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. Oncogene 2010;345-55.
- 16. Zhang Y, Hagedorn CH, Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta 2011;: 893-908.
- 17. Yang S, Chen J, Guo Y, Lin H, Zhang Z, Feng G, et al. Identification of prognostic biomarkers for response to radiotherapy by DNA microarray in nasopharyngeal carcinoma patients. Int J Oncol 2012;: 1590-600.
- 18. López-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA, Colás B. SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem 2011;89-98.
- 19. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;928-42.
- 20. Macaluso M, Montanari M, Cinti C, Giordano A. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol 2005;452-7.
- 21. Shimura T. Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat Res 2011;539-44.
- 22. Lopez-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA, Colas B. SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem 2011;89-98.
- 23. Vinayanuwattikun C, Sriuranpong V, Tanasanvimon S, Chantranuwat P, Mutirangura A. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer. J Thorac Oncol 2011;1818-25.
- 24. Insabato L, Amelio I, Quarto M, Zannetti A, Tolino F, et al. Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors. Oncology 2009;378-84.
- 25. Baker SJ, Reddy EP. Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010;573-86.
- 26. Zhang Y, Hagedorn CH, Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta 2011;893-908.
Language: English
Page range: 40 - 49
Published on: Jan 22, 2014
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2014 Gang Peng, Rubo Cao, Jun Xue, Pindong Li, Zhenwei Zou, Jing Huang, Qian Ding, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.